Avista boosts drug active capacity | November 20, 2017 Issue - Vol. 95 Issue 46 | Chemical & Engineering News
Volume 95 Issue 46 | p. 12 | Concentrates
Issue Date: November 20, 2017

Avista boosts drug active capacity

Department: Business
Keywords: Outsourcing, manufacturing, research
[+]Enlarge
One of three new 200-L Pfaudler reactors paired with GL Filtration dryers at Avista's facility.
Credit: Avista
A photo of Avista's new facility in Longmont, Colo.
 
One of three new 200-L Pfaudler reactors paired with GL Filtration dryers at Avista's facility.
Credit: Avista

Avista Pharma Solutions has doubled active pharmaceutical ingredient (API) production capacity at its Longmont, Colo., site. As part of the project, the company upgraded three API manufacturing suites and added a fourth. Avista was formed in 2015 when Ampersand Capital Partners combined Array BioPharma’s chemistry facility in Longmont with Scynexis’s contract R&D assets in Research Triangle Park, N.C., and Accuratus Lab Services in Eagan, Minn.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment